Fusion Pharmaceuticals Inc.

fusionpharma.com
Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Compass Rose
Next-generation radiopharmaceuticals for precision medicine (antibody Conjugate for Lung Cancer), prividing a safer approach to targeted radiotherapy by helping the drug clear from normal, healthy tissues and reducing toxicity.

Related news

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.